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Abstract 
The purpose of this study was to fabricate the transdermal films of a low oral bioavailability drug Nisoldipine 
(5%) employing a combination of hydrophilic and hydrophobic polymer. The films were developed by solvent 
evaporation technique. The polymeric matrix contains Ethyl cellulose/Eudragit RS 100 and HPMC E-15. The 
effect of hydrophilic and hydrophobic polymers on the physicochemical and mechanical properties, such as 
weight variation, thickness, moisture uptake, moisture content, and tensile strength, elongation at break was 
evaluated.  In-vitro release and ex-vivo permeation across the rat skin was studied using the Franz diffusion 
cells. The tensile strength of the NS6 and NSE5 were found to be 0.9±0.21 and 1.9±0.10 kg/mm2.The films 
developed in the ratio of 15:5 (NS6) and 12.5:7.5 (NSE5) using HPMC E15-ERS 100 and HPMCE15- EC 
showed maximum drug release and ex-vivo permeation (NS6: 953 µg and NSE5:895 µg).The flux of NS6 and 
NSE5 was 13.03 µg/cm2/hr and 11.77 µg/cm2/hr. The data of release kinetics using different kinetic models 
indicated that release from optimized formulations followed zero order release kinetics with non fickian 
diffusion pattern.  FTIR studies revels that there was no interaction between the drug and polymer and were 
found to be compatible. Matrix type transdermal films can be fabricated employing hydrophilic and 
hydrophobic polymers with suitable mechanical properties. 
------------------------------------------------------------------------ 
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1. Introduction  
The transdermal route of administration is considered as one of the potential route for the local and systemic 
delivery of drugs [1-2]. Drug delivery through skin has a number of significant advantages over many other 
routes of drug administration, such as painless and simple application,  ability to avoid problems of gastric 
irritation, avoid hepatic first-pass metabolism thereby increasing the bioavailability of drug, pH and emptying 
rate effects, reduce the risk of systemic side effects by minimizing plasma concentrations compared to oral 
therapy, rapid termination of therapy by removal of the device or formulation, provide a sustained release of 
drug at the site of application;  the reduction of fluctuations in plasma levels of drugs, and avoid pain associated 
with injections [ 3-4] . 
Nisoldipine is a calcium antagonist of the 1, 4-dihydropyridene class, can reduce vascular resistance and blood 
pressure by inhibiting calcium uptake of myocardial and smooth muscle cells [5].Immediate-release (5 and 10 
mg) and controlled-release (10, 20, 30 mg and 40 mg) oral preparations for NSP are available in the market 
for the treatment of hypertension and angina pectoris [6-8]. Following oral administration, Nisoldipine is 
rapidly absorbed from the gastrointestinal tract, but the oral bioavailability remains low (5%) because of 
significant first-pass hepatic metabolism [9]. Nisoldipine also has a short plasma half-life of 7-12 hrs. Long term 
therapy of hypertension by Nisoldipine oral administration may result in poor patient compliance because of low 
bioavailability and short plasma half-life, leading to increase frequency of administration, therefore an 
alternative route of administration is needed. The aims of the present study was to develop matrix type 
transdermal films of NSP employing various ratios of hydrophilic and hydrophobic polymer combinations, 
evaluate the  physicochemical characterization and mechanical properties and conduct the in vitro release and 
ex-vivo permeation studies through rat abdominal skin. The purpose was to provide the delivery of the drug at a 
controlled rate across intact skin to improve the drug concentrations in layers of skin.  
2. Materials and Methods 
2.1 Materials 
Nisoldipine was obtained as gift sample from Orchid Chemicals and Pharmaceuticals, Chennai, Tamilnadu, 
India. Eudragit RS100, Ethyl cellulose, HPMC E-15 were obtained as gift samples from Dr. Reddy’s 
Laboratories, Hyderabad, India. All other chemicals and solvents used were of analytical reagent grade. 
2.2. Methods 
2.2.1. Preparation of transdermal Films 
Nisoldipine matrix type transdermal films were prepared by film casting technique using different ratios of 
Eudragit RS 100 or Ethyl cellulose and HPMC E-15. Weighed quantity of polymers was dissolved in 20mL of 
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solvent mixture consisting of 1:1 ratio of dichloromethane and Methanol. The polymeric solution was vortexed 
and kept for swelling for 8 hrs. Weighed quantity of Nisoldipine was dissolved in 5 mL of solvent mixture. The 
drug solution and propylene glycol (15% W/V) as plasticizer was added to the polymeric solution and was 
vortexed for 5 minutes. The mixture was kept aside for 10 minutes to remove the entrapped air bubbles and was 
transferred into petri plates. The rate of evaporation of the solvent was controlled by inverting cut funnel over 
the petri plate. Drying of these films was carried out at room temperature for overnight and then in vacuum oven 
at room temperature for 10 hrs. The films were carefully removed, cut to the size each having 1.78 cm X 1.78 
cm (3.56cm2) and stored in desiccators.  
2.2.2. Weight and thickness variation assessment 
Each fabricated film was prepared in triplicate and ten circular films having an area 1.78 cm X 1.78 cm (3.56 
cm2) were cut from each plate. The weight was measured using digital balance. The thickness of film was 
measured at different sites using digital screw gauge.  
2.2.3. Estimation of drug content  
The fabricated polymeric films were assayed for drug content. Three films from each formulation series were 
taken, cut into small pieces and was dissolved in 10 mL of solvent mixture (1:1 ratio of DCM: methanol). The 
resulting mixture was diluted up to 100 mL with pH 7.4methanolicphosphate buffer (40:60).  The solution was 
filtered through membrane filter (0.45 µ) and the drug content was measured using UV spectrophotometer. 
2.2.4. In vitro drug release studies  
Drug release from the transdermal patch was studied using vertical Franz diffusion cells with a receptor 
compartment capacity of 17mL. The patch of 3.56cm2 was mounted on the dialysis membrane placed in between 
the donor and receptor compartment of the diffusion cell. The receptor compartment was filled with methanolic 
phosphate buffer pH 7.4 (40:60). The whole assembly was place on the magnetic stirrer and solution in the 
receptor compartment was stirred continuously using magnetic beads at 350rpm, the temperature was 
maintained at 37 ±0.5 °C. An aliquot of 2mL were withdrawn at pre-determined time intervals and analyzed for 
the drug content spectrophotometrically. The receptor phase was replenished with an equal volume of 
methanolicphosphate buffer pH 7.4 (40:60) at each sample withdrawal to maintain the in vitro sink conditions 
[10].  
2.2.5. In –vitro release Kinetics  
Different kinetic models, zero order, first order [11], Highuchi and Kosrsmeyer expressions [11-12]were applied 
to interpret the drug release kinetics to know the mechanism of drug release from these matrix systems with the 
help of equation’s (1- 4 ). 
Mt=Mo + Ko t -----------------------(1) 
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2016) Volume 23, No  1, pp 1-14 
 
4 
 
LnMt=LnMo + K1 t ----------------(2) 
Mt=KH t1/2---------------------------(3) 
Mt/M∞ = Kktn -------------------------(4) 
Mt cumulative amount of drug release at time t; Mo, is the initial amount of drug Ko, K1, KH and Kk are rate 
constants for zero order, first order, Highchi and Korsemeyer model respectively; Mt/M∞ is the fraction of drug 
release at time t n, release exponent indicative of the operating release mechanism. The correlation coefficient 
values (r2) presented in table 3. 
2.2.6. Percentage moisture uptake  
Circular films having an area 1.78 cm X 1.78cm (3.56 cm2) were weighed accurately and placed in desiccators 
containing 100 mL of standard of aluminium chloride solution in order to maintain 79.5 % RH. After 72 hrs, the 
films were taken out and weighed. The percentage of moisture uptake was calculated as difference between the 
final and initial weight with respect to the initial weight [13]. 
2.2.7. Percentage moisture content  
The prepared films were weighed accurately and kept in a vacuum desiccators containing fused calcium chloride 
at room temperature for 24 hrs. After 24 hrs the patch was individually weighed until they showed a constant 
weight. The percentage of moisture content was calculated as a difference between initial weight and final 
weight with respect to final weight [14]. 
2.2.8. Mechanical Properties  
Mechanical properties of the fabricated films were evaluated using a microprocessor based advanced force 
gauze equipped with a motorized test stand (Ultra Test, Mecmesin, West Sussex, and UK), equipped with 25 kg 
load cell. The Tensile strength (T.S) and elongation of break (E.B) were measured using the film strip (60 × 
10mm) free from air bubbles or any physical imperfections. The film strip (60 × 10mm) was held between two 
clamps positioned at a distance of 3 cm. During measurement, the top clamp at a rate of 2 mm s-1pulled the 
strips to a distance till the film broke. The force and elongation were measured when the films were broken. The 
mechanical properties were calculated using the equation 5 and 6. 
T.S (Kg mm-2) = [Force at break (Kg)/ Initial cross sectional area of the patch (mm -2)] .......  (5). 
E.B (%mm-2) = [Increase in length (mm)/ Original length × 100/ Cross sectional area (mm-2)....  (6) 
2.2.9. Flatness assessment  
The construction of a film strip cut from a drug loaded matrix film is an indicator of its flatness. Longitudinal 
strips (1.5 cm × 0.75 cm) were cut out from each film: one film each from the centre, left side, and right side. 
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The films were kept at room temperature for 1 hr after measuring the initial lengths of films. The change in the 
length due to non-uniformity in flatness were measured. Flatness of films was calculated by measuring 
constriction of strips and a zero percent of constriction was considered to be equal to 100% flatness [15].  
% construction = L1 –L2/L2 ×100 
% construction = Initial length of each strip (cm) - Final length of each strip (cm) /Final length of the strip (cm) 
×100 
2.2.10. Folding Endurance 
The folding endurance was measured manually for the prepared films to assess the strength and flexibility of 
film. Folding endurance is defined as the number of folds required to break the polymeric film. This was 
determined by repeatedly folding a small strip of film (5 × 5 cm) at the same place till it broke. The number of 
time the film could be folded at the same place without breaking/cracking was the folding endurance value of 
that prepared transdermal film [15]. 
2.2.11. Preparation of rat abdominal skin for ex-vivo permeation studies  
Wistar rats weighing 150-200g were sacrificed using anaesthetic ether. The full thickness abdominal skin was 
removed and hair was carefully trimmed with electrical clippers. The epidermis was soaked for 30 sec at 60 ° 
and fatty layer of epidermis was removed carefully. The epidermis was washed with normal water and was used 
for ex-vivo permeation studies [16]. 
2.2.12. Ex-Vivo permeation studies  
Ex-vivo permeation studies were conducted using fabricated Franz diffusion Cell with a surface area of 3.56 
cm2. The prepared rat abdominal skin was cut into desired size and was placed between the receptor and donor 
compartments of the diffusion cell. The fabricated patch was cut in 3.56 cm2 and was placed over the skin. The 
stratumcorrneum side of the skin was kept in intimate contact with the release surface of the films.  
The donor compartment was kept on the receptor compartment and kept tightly with the help of clamps. 
Phosphate buffer saline pH 7.4 was used as the receptor fluid. It was filled into the receptor compartment 
through the sampling port and checked for the absence of any air bubble under the skin. The entire assembly 
was kept on the magnetic stirrer. A magnetic bead was placed in the receptor compartment and was rotated at a 
constant speed for maintaining the hydrodynamics of the fluid constant throughout the study. The temperature 
of the receptor fluid was maintained at 37 ± 2 °C with the help of thermostat.1.5 mL of sample aliquots was 
collected at pre-determined time points and was injected into the HPLC system after filtering through 0.25 µm 
membrane filters and suitably diluting it. 
The samples were replaced with the same volume of phosphate buffer saline pH 7.4 to keep the volume of the 
receptor compartment constant and also to ensure an intimate contact between the dermal surface of the skin and 
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the receptor solution. Cumulative amounts of drug permeated in µg/cm2 were calculated and was plotted against 
time. Drug flux (µg/cm2/ hr) at steady state was calculated by dividing the slope of the linear portion of the 
curve by the area of the exposed skin surface (3.56 cm2) and the permeability coefficient was calculated by 
dividing the flux by initial drug loaded as shown in table 4. 
2.2.13. Skin irritation studies 
Skin irritation studies were performed on healthy rabbits weighing to an average weight of 1.5 to 2.25 kg. The 
dorsal surface (50cm2) of the rabbits was cleaned, and the hair was removed by shaving. The skin was cleansed 
with rectified spirit. A film (NS6 and NSE5) was placed over the skin with the use of adhesive tape and was 
removed after 24 hrs to check the skin irritation [17].  
2.2.14. FTIR Studies 
Fourier trasform infrared (FTIR) technique was used to study the physical and chemical interaction between 
drug and excipients. FTIR spectrum of Nisoldipine, physical mixtures of Nisoldipine: HPMC E-15: Eudragit RS 
100 and Nisoldipine: HPMC E-15: Ethyl cellulose was recorded using KBr mixing method on FTIR (FTIR-
1700, Shimadzu, Kyoto, Japan). IR spectra are shown in Figures 7 a, b & c.  
2.2.15. Stability studies 
The stability studies were conducted for the optimized formulations. The films from different formulations were 
wrapped in aluminium foil and stored in a petri dish at temperature of 40 ± 2 °C, 75 ± 5 % RH for 6 months. 
The samples were withdrawn at regular interval of 1, 2, 3 and 6 months and analysed for drug content using the 
HPLC. 
3. Results and Discussions 
3.1. Formulation of Nisoldipine transdermal films 
NSP transdermal films were fabricated employing various concentrations of Ethyl cellulose (EC) or Eudragit 
ERS 100 and HPMC E-15. The films were fabricated initially with 1: 10 ratio of Drug: polymer. The obtained 
films were very thin and were getting adhered to the petri plates and it was difficult to remove. The polymer 
concentration was then increased to 1:20. As the concentration of polymer was increased, films with good 
thickness were obtained and the films could accommodate required amount of the drug.  
The films were pale yellow in colour due to the colour of NSP pure drug. The films were appearing transparent 
suggesting that the drug was completely dispersed in the polymeric matrix. The weight variation test 
observations for the fabricated films are shown in table 2. Results indicate the uniformity of weight of the films 
according to the %RSD values, which is less than 6. 
Thickness of the films in the respective series varied from 210±14.2 µm to 225±12.4 µm (NS) and 209±15.3 µm 
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to 220±14.8 µm (NSE). The results (table 2) suggest that change in polymer concentration did not product any 
significant change in the thickness of the films. 
Table 1 : NSP: Nisoldipine; ; HPMC E15: Hydroxy propyl Methyl cellulose E15;ERS 100: Eudragait RS 100; 
EC:Ethyl cellulose. Solvent system: 20mL of 1:1 of DCM and Methanol. Plasticizer 15% w/v of propylene 
glycol. Drug content: 4mg in each film 1.78 x1.78 cm2 
Formulation 
Ingredients (Parts) 
NSP HPMC E15 ERS 100 EC 
NS1 1 … 20 … 
NS2 1 5 15 … 
NS3 1 7.5 12.5 … 
NS4 1 10 10 … 
NS5 1 12.5 7.5 … 
NS6 1 15 5 … 
NSE1 1 … … 20 
NSE2 1 5 … 15 
NSE3 1 7.5 … 12.5 
NSE4 1 10 … 10 
NSE5 1 12.5 … 7.5 
NSE6 1 15 … 5 
 
Table 2: Physicochemical properties of fabricated transdermal films of Nisoldipine 
Formulation Code Weight (mg) Thickness (µm) Assay (%) 
NS1 184 ±4.5 220±14.5 97.8±4.5 
NS2 190±5.5 225±12.4 100.2±1.5 
NS3 188±5.2 210±14.2 96.4±4.2 
NS4 183±4.3 218±12.5 95.1±2.5 
NS5 184±5.4 221±14.3 101.1±1.2 
NS6 190±5.7 215±10.5 99.9±4.5 
NSE1 186±4.3 218±15.2 98.1±2.3 
NSE2 189±5.4 220±14.8 97.5±4.1 
NSE3 190±5.8 209±15.3 98.0±1.7 
NSE4 183±4.7 216±14.6 97.2±2.5 
NSE5 185±5.1 220±12.8 99.3±4.3 
NSE6 188±4.9 210±12.2 100.2±1.2 
 
The drug content uniformity was found to be good and was represented in table 2. The drug content in films 
fabricated with HPMC and ERS was ranged from 97.8±4.5 to 101.1±1.2 whereas films fabricated with 
combination HPMC & EC was ranged from 97.5±4.1 to 100.2±1.2 respectively.  
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2016) Volume 23, No  1, pp 1-14 
 
8 
 
3.2. In-vitro drug release studies 
The in -vitro release profiles of NSP form the fabricated films were shown in figure 1a and 1b. Formulations 
NS6 (2440 µg) and NSE5 (2235 µg) showed maximum amount of drug release in the respective series with zero 
order (r2> 0.992& 0.997) release kinetics evidenced from the correlation coefficients.  
 
Figure1a: In -vitro release profiles of NSP films (NS) 
 
 
Figure 1b: In -vitro release profiles of NSP films (NSE) 
The release profiles of the formulations indicate that the drug release from the films is governed by the polymer 
concentration. As the Hydrophilic polymer concentration increases in the formulations, the rate of drug release 
increases substantially. The drug release kinetics was calculated for all the formulations and is represented in 
Table 3. The release exponent (n≥0.50) evidenced non Fickian model of release pattern from optimized 
formulations.  
3.3. Percentage moisture uptake and moisture content 
The moisture absorption ranged from 0.05 to 1.74 % in NS series and 0.04 to 1.94 % in NSE series. The 
moisture content in the films ranged from 0.02 to 0.36 % in NS series and 0.03 to 0.39 % in NSE series and is 
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represented in Figure 2. The low moisture absorption protects the transdermal films from microbial 
contamination and small moisture content prevents the films from becoming brittle.  
Table 3: in vitro drug release kinetics of NSP transdermal films 
Formulation code Zero order First order Higuchi Peppas Korsemeyar (n) 
NS1 0.991 0.994 0.992 0.136 
NS2 0.993 0.994 0.993 0.221 
NS3 0.994 0.992 0.991 0.136 
NS4 0.946 0.961 0.957 0.493 
NS5 0.978 0.978 0.981 0.487 
NS6 0.992 0.967 0.991 0.552 
NSE1 0.994 0.992 0.991 0.420 
NSE2 0.996 0.996 0.998 0.079 
NSE3 0.997 0.997 0.995 0.027 
NSE4 0.975 0.983 0.980 0.441 
NSE5 0.97 0.933 0.968 0.552 
NSE6 0.991 0.996 0.994 0.578 
 
 
Figure 2:  Percentage moisture uptake and moisture content 
3.4. Mechanical properties of films 
A soft and weak polymer is characterized by low TS and E/B; a hard and brittle polymer is defined by a 
moderate TS and low E/B; a soft and tough polymer is characterized by a moderate TS and high E/B; where as a 
hard and tough polymer is characterized by a high TS and E/B [18]. Thus a suitable transdermal film should 
possess a high TS and E/B.  
The results of tensile strength and elongation at break are indicated in the table 3 and figure 3. The 
formulation.NS1 and NSE4 exhibited greater values of TS (2.6 kg/mm 2 and 2.1 kg/mm 2 for NS1 and NSE4 
respectively).  Optimized formulations NS6 (91.4±4.23mm2) and NSE5 (88.9±10.13 mm2) showed greater 
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values of elongation at break in their respective series.  
Thus as the concentration of hydrophilic polymer HPMC E-15 increases in NS series the TS decreases and E/B 
increases. Both TS and E/B found to be increased with increase in concentration of HPMC E-15 in NSE film. 
The above observations reveal that the formulation NS6 and NSE5films were found to be strong and were not 
brittle (18). 
Table 3: Results of tensile strength and elongation at break of fabricated films 
Formulation code T.S (kg/mm2) EB (%mm2) 
NS1 2.6±0.50 16.4±1.38 
NS2 1.9±0.22 27.5±2.50 
NS3 2.0±0.31 69.2±6.23 
NS4 1.4±0.15 86.4±7.98 
NS5 1.1±0.11 88.6±5.90 
NS6 0.9±0.21 91.4±4.23 
NSE1 1.0±0.09 29.8±4.80 
NSE2 1.3±0.13 31.6±7.31 
NSE3 1.7±0.32 71.0±6.62 
NSE4 2.1±0.21 76.7±6.91 
NSE5 1.9±0.10 81.2±8.22 
NSE6 2.0±0.13 88.9±10.13 
 
 
Figure 3: measurement of tensile strength and elongation at break 
3.5. Ex-vivo permeation studies of Nisoldipine transdermal films 
The results of the ex-vivo permeation studies from the NSP films are presented in table 4 and figure 4 & 5.The 
maximum drug permeation was observed in NS6 and NSE5.  The films NS6 (13.03µg/cm2h-1/) and NSE5 
(11.77µg/cm2h-1) were considered to be the optimum formulations.   
The drug NSP was found to be released from transdermal films  and permeated though the rat abdominal skin 
thus it can could be possibly permeated though the human skin. The permeation pattern was found to be similar 
with the in vitro release pattern.  
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Table 4: CR: cumulative amount of NSP released in 24 h; CP: cumulative amount of NSP permeated in 24 h; 
K: permeability coefficient 
Formulation Code CR 24  (µg) CP 24  (µg) Flux (µg/cm-2/h-1) K (CM-1) 
NS1 689 356 5.52 1.38 
NS2 738 396 5.76 1.44 
NS3 780 456 6.35 1.59 
NS4 1001 738 10.45 2.61 
NS5 1600 806 10.85 2.71 
NS6 2440 953 13.03 3.26 
NSE1 650 336 5.33 1.33 
NSE2 719 364 5.63 1.41 
NSE3 759 640 9.40 2.35 
NSE4 983 680 9.93 2.48 
NSE5 2235 895 11.77 2.94 
NSE6 1670 842 11.43 2.86 
 
Figure 4 : Ex-vivo permeation profiles of NSP from films fabricated with  HPMC E15& ERS10 
 
Figure 5: Ex-vivo permeation profiles of NSP from films fabricated with HPMC E15& Ethyl cellulose 
3.6. FTIR studies  
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The FTIR studies shown in Fig.6 indicate no interaction between the drug and polymers. Thus these polymers 
could be used in sustained/controlled release matrix type tansdedrmal films. 
 
Figure 6: FT-IR Spectra of ( i) Nisoldipine (NSP) Pure drug (ii) Physical mixture of NSP+HPMC E15+ERS 
100 (iii) Physical mixture of NSP+HPMC E15+Ethyl cellulose 
3.7. Stability Studies 
The stability studies of the optimized formulations (NS6& NSE5)  were carried out as per ICH guidelines. On 
storing the tansdermal films at 40 ±2°C/75±5% RH for 6 months 1.48% (NS6) and 1.78% (NSE5) degradation 
was observed. Hence the observed degradation is less than 5 % from initial value in the formulation, a shelf life 
of 2 years can be proposed. 
4. Conclusions 
Matrix type transdermal films of NSP could be fabricated with suitable mechanical properties. Further studies 
could be carried out in human beings for the assessment of pharmacokinetic parameters.  
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